PHILADELPHIA--(BUSINESS WIRE)--May 3, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB - News), will today present the audited results of the Company’s experimental therapeutic Ampligen® clinical trials in Chronic Fatigue Syndrome at the 5th International Conference on HHV-6&7 in Barcelona, Spain. The presentation shows that the tests achieved improvements far above the levels considered medically significant.
